๐งฌ CAPR rockets +86% as FDA clock ticks on Deramiocel โ DMD decision due Aug 22
Capricor Therapeutics $CAPR is surging in early trading ahead of a critical FDA decision on its Duchenne muscular dystrophy drug Deramiocel, with a PDUFA target date of August 22. Phase 3 HOPE-3 data published in The Lancet showed the therapy slowed upper-limb function decline by 54% vs. placebo โ a statistically significant result. Cantor Fitzgerald upgraded the stock on Aug 14 and set a $28 price target. Is this a buy-the-news setup, or too risky with binary FDA risk days away? Not financial advice.
โก 51 buzzing
385 views
๐ 0 subscribed